Cytogenetic and molecular cytogenetic investigations in relapse of B-cell chronic lymphocytic leukemia

被引:0
作者
S. V. Andreieva
K. V. Korets
I. M. Skorokhod
O. E. Ruzhinska
机构
[1] National Academy of Medical Sciences of Ukraine,Institute of Hematology and Transfusiology
[2] Ministry of Health of Ukraine,Scientific
来源
Cytology and Genetics | 2017年 / 51卷
关键词
chronic lymphocytic leukemia; bone marrow; chromosomal abnormalities; relapse;
D O I
暂无
中图分类号
学科分类号
摘要
Сhromosomal abnormalities have been analyzed in bone marrow cells of 61 patients with relapse of B-cell chronic lymphocytic leukemia. The cytogenetic results have allowed the structural stratification of the obtained karyotypes into ten groups of clones: normal, normal/near tetraploid, abnormal/normal, abnormal/ near tetraploid/normal, evolution of clonal chromosome abnormalities; evolution of clonal chromosome abnormalities/normal, evolution of clonal chromosome abnormalities/near tetraploid/normal, independent clones, independent/normal clones; and independent/near tetraploid/normal clones. The identified structural rearrangements included translocations, deletions, insertions, and duplications; however, deletions with the involvement of bands 17p12, 13q12–q14, 11q14, and 11q23 dominated (63.8%). The application of i-FISH helped to show the presence of one to four abnormalities per karyotype. The identified cytogenetic and molecular cytogenetic rearrangements may signify a multilevel nature of the process underlying the development of resistant karyotypes. The results obtained under both methods have revealed the presence of a heterogenic cell population with possibly different levels of chemotherapy resistance.
引用
收藏
页码:155 / 161
页数:6
相关论文
共 153 条
[1]  
Hallek M.(2013)Chronic lymphocytic leukemia: 2013 update on prognosis risk stratification and treatment, Am. J. Hematol. 88 803-816
[2]  
Oscier D.(2013)Chronic lymphocytic leukemia. Do we need novel prognostic markers? in Hematology Education: The Education Program for the Annual Congress of the European Hematology Association 7 121-130
[3]  
Shahjahani M.(2015)Molecular basis of chronic lymhocytic leukemia diagnosis and prognosis Cell. Oncol. (Dordr.) 38 93-109
[4]  
Mohammadiasl J.(2011)Prognostic markers in chronic lymphocytic leukemia Vnitrni Lekarstvi 57 847-857
[5]  
Noroozi F.(2014)Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by notch1 mutations Blood 123 4101-4110
[6]  
Seghatoleslami M.(2009)Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group J. Clin. Oncol. 27 3994-4001
[7]  
Shahrabi M.(2009)Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion TP53 mutation, p53–p21 dysfunction, and miR34a in a prospective clinical trial, Blood 114 2589-2597
[8]  
Saba F.(2013)Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia Blood 121 1403-1412
[9]  
Saki N.(2014)Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data Am. J. Hematol. 89 249-255
[10]  
Motyckova M.(2010)TP53 mutation and survival in chronic lymphocytic leukemia J. Clin. Oncol. 28 4473-4479